| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print June 16, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardiovascular Research, Pfizer, Inc., Saint Louis, MO 63167
Corresponding Author: b.ganesh.bhat{at}pfizer.com
Blocking intestinal absorption of bile acids is a target for reducing plasma levels of LDL cholesterol. This can be achieved by inhibiting the ileal apical sodium co-dependent bile acid transporter (ASBT)† resulting in increased fecal bile acid excretion and accelerated hepatic utilization of cholesterol for bile acid synthesis. SC-435 was identified as a specific and potent inhibitor of ASBT, with an IC50 of 1.5 nM, in BHK cells stably transfected with the human ASBT gene. Dietary administration of 3 to 30 mg/kg SC-435 to ApoE-/- mice increased fecal bile acid excretion by more than 2.5-fold and had no significant effect on fecal neutral sterol excretion. Dietary administration of 10 mg/kg SC-435 for 12 weeks to ApoE-/- mice reduced serum total cholesterol by 35% and inhibited aortic root atherosclerotic lesion area by 65%. In agreement with the compensatory mechanism, in vivo inhibition of ileal ASBT resulted in significant increases in hepatic mRNA levels of cholesterol 7a-hydroxylase and HMG-CoA reductase. Treatment of ApoE-/- mice also resulted in decreased expressions of ileal bile acid binding protein (IBABP) and hepatic nuclear hormone receptor small heterodimer partner (SHP), direct target genes of the nuclear hormone receptor, farnesoid X receptor (FXR) suggesting a possible role of FXR in SC-435 mediated modulation of cholesterol homeostasis. SC-435 treatment in dogs reduced serum total cholesterol levels by < 15% and in combination with atorvastatin treatment, caused an additional reduction of ~25% was observed. These results suggest that specific inhibition of ASBT with SC-435 is a novel therapeutic approach for the treatment of hypercholesterolemia resulting in a decreased risk for coronary artery disease.
Revised on May 7, 2003
Accepted on June 10, 2003
SC-435, a potent inhibitor of the Apical sodium Co-dependent bile acid transporter,reduces Atherosclerotic lesions in ApoE-/- mice
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C Thomas, J-F Landrier, D Gaillard, J Grober, M-C Monnot, A Athias, and P Besnard Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences Gut, September 1, 2006; 55(9): 1321 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Hruz, C Zimmermann, H Gutmann, L Degen, U Beuers, L Terracciano, J Drewe, and C Beglinger Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis Gut, March 1, 2006; 55(3): 395 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Claudel, B. Staels, and F. Kuipers The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2020 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Alrefai, Z. Sarwar, S. Tyagi, S. Saksena, P. K. Dudeja, and R. K. Gill Cholesterol modulates human intestinal sodium-dependent bile acid transporter Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G978 - G985. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
